News & Events

PHASE 1B/2A Clinical trial started

13 Apr|

The Nerofe Phase 1B/2A trial with high risk MDS and AML patients is taking place at the University of Miami Sylvester Comprehensive Cancer Center.

ISK received the FDA’s approval to start Phase 1b/2a with AML patients

09 Jan|

Cooperation with Harvard Medical School (MGH)

27 Oct|

ISK has signed an agreement for cooperation with Harvard Medical School for drug development to treat neurodegenerative diseases